Zobrazeno 1 - 10
of 484
pro vyhledávání: '"Grace, Julia"'
Autor:
GRACE, JULIA juliagrace@xtra.co.nz
Publikováno v:
Teachers Matter. 2024, Issue 61, p36-37. 2p.
Autor:
Wallace, Janet
Publikováno v:
Canadian Organic Grower. Spring2010, Vol. 7 Issue 2, p48-51. 4p. 3 Black and White Photographs.
Autor:
Khouri, Issa F., Saliba, Rima M., Giralt, Sergio A., Lee, Ming-Sheng, Okoroji, Grace-Julia, Hagemeister, Fredrick B., Korbling, Martin, Younes, Anas, Ippoliti, Cindy, Gajewski, James L., McLaughlin, Peter, Anderlini, Paolo, Donato, Michele L., Cabanillas, Fernando F., Champlin, Richard E.
Publikováno v:
In Blood 15 December 2001 98(13):3595-3599
Autor:
Amin M. Alousi, Carlos Bueso-Ramos, Zaher Chakhachiro, Stefan O. Ciurea, U. Popat, P. Anderlini, Issa F. Khouri, Richard E. Champlin, M. Körbling, Oran Betul, Grace Julia Okoroji, Barry I. Samuels, L. Jeffrey Medeiros, Rima M. Saliba
Publikováno v:
Cancer. 119:3318-3325
BACKGROUND In the current study, the authors report the results of 39 patients with mantle cell lymphoma (MCL) who were treated with chemotherapy and high-dose rituximab-containing autologous stem cell transplantation (ASCT) during their first diseas
Autor:
Roy B. Jones, Rima M. Saliba, Anas Younes, Martin Korbling, Luis Fayad, Barbara Pro, Issa F. Khouri, Michele L. Donato, Paolo Anderlini, Marcos de Lima, Daniel R. Couriel, Grace Julia Okoroji, Sandra Acholonu, Peter McLaughlin, Elizabeth J. Shpall, John T. Manning, Richard E. Champlin, Farzaneh Maadani, Segio Giralt, Chitra Hosing
Publikováno v:
Journal of Clinical Oncology. 23:2240-2247
Purpose We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with re
Autor:
Rima M. Saliba, Sandra Acholonu, Uday R. Popat, Naoto T. Ueno, Paolo Anderlini, Roy B. Jones, Richard E. Champlin, Muzaffar H. Qazilbash, Marcos de Lima, Sergio Giralt, Grace Julia Okoroji, Yago Nieto, Chitra Hosing, Borje S. Andersson, Celina Ledesma
Publikováno v:
Leukemia & Lymphoma. 53:1239-1241
Progressive disease remains the main cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for Hodgkin lymphoma (HL), and the role of donor leukocyte infusions (DLIs) in the management of disease recurrence is still bei
Autor:
Zaher I, Chakhachiro, Rima M, Saliba, Grace-Julia, Okoroji, Martin, Korbling, Amin M, Alousi, Oran, Betul, Paolo, Anderlini, Stefan O, Ciurea, Uday, Popat, Richard, Champlin, Barry I, Samuels, L Jeffrey, Medeiros, Carlos, Bueso-Ramos, Issa F, Khouri
Publikováno v:
Cancer. 119(18)
In the current study, the authors report the results of 39 patients with mantle cell lymphoma (MCL) who were treated with chemotherapy and high-dose rituximab-containing autologous stem cell transplantation (ASCT) during their first disease remission
Autor:
Anderlini, Paolo, Saliba, Rima, Acholonu, Sandra, Okoroji, Grace-Julia, Andersson, Borje S., Jones, Roy, Popat, Uday R., Hosing, Chitra M., Nieto, Yago, Qazilbash, Muzaffar H., Ueno, Naoto T., Giralt, Sergio A., de Lima, Marcos J, Champlin, Richard E.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e87f9f5d449402c81b0f959eac67f37d
https://europepmc.org/articles/PMC4493857/
https://europepmc.org/articles/PMC4493857/
Autor:
Gabriela Rondon, Richard E. Champlin, Grace-Julia Okoroji, Daniel R. Couriel, Asif Rashid, Rima M. Saliba, Amin M. Alousi, Sergio Giralt
Publikováno v:
Bone marrow transplantation. 47(1)
One challenge in designing clinical trials for treatment of acute GVHD (aGVHD) is the lack of an established standardized end point to measure the success of therapies. To facilitate assessment of end points in clinical trials for treatment of aGVHD
Autor:
Elizabeth J. Shpall, Muzaffar H. Qazilbash, Laura L. Worth, Uday R. Popat, Roland Bassett, Richard E. Champlin, Paolo Anderlini, Sergio Giralt, Grace Julia Okoroji, Sandra Acholonu
Publikováno v:
Leukemialymphoma. 52(1)
Twenty severe aplastic anemia (SAA) patients underwent allogeneic stem cell transplantation (allo-SCT) with fludarabine (FLU), cyclophosphamide and antithymocyte globulin from a matched related (n=7, age ≥ 40) or unrelated donor (n=13, any age). Me